¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

¼¼ºê¶õ½ºº´¿ø ´ëÇѹé¹ÝÁõÇÐȸ Á¦ 10Â÷ ½ÉÆ÷Áö¾ö : 2019-04-06

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
¼¼ºê¶õ½ºº´¿ø ´ëÇѹé¹ÝÁõÇÐȸ Á¦ 10Â÷ ½ÉÆ÷Áö¾ö : 2019-04-06
±³À°ÀÏÀÚ : 2019-04-06
±³À°Àå¼Ò : ¼¼ºê¶õ½ºº´¿ø Á¾ÇÕ°ü 3Ãþ 337È£  
±³À°ÁÖÁ¦ : ´ëÇѹé¹ÝÁõÇÐȸ Á¦ 10Â÷ ½ÉÆ÷Áö¾ö
ÁÖÃÖ±â°ü : ´ëÇÑÇǺΰúÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ´ëÇѹé¹ÝÁõÇÐȸ  
´ã´çÀÚ : ¿À»óÈ£
¿¬¶ôó : 02-2228-2080  
À̸ÞÀÏ : kda@derma.or.kr      
±³À°Á¾·ù : ÇǺΰú      
Âü¼®¿¹»óÀοø : 100¸í
Èñ¸ÁÆòÁ¡ : 4Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 4 ½Ã°£ 20ºÐ  
¼¼ºÎ¼ö°­·á : 20,000¿ø      
ºñ°í ÇöÀåµî·Ï¸¸ °¡´É: ÇǺΰúÀü¹®ÀÇ 2¸¸¿ø, ÇǺΰúÀü°øÀÇ 1¸¸¿ø      

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 04-06 337È£ 13:10~13:30 Interplay between oxidative stress and immune system  ¿À»óÈ£(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 04-06 337È£ 13:30~13:50 A symphony of various kinds of immune cells responsible for vitiligo  ÀÌ»óÈÆ(¼øõÇâÀÇ´ë) 
±³À°½Ã°£ 04-06 337È£ 13:50~14:10 Melanocyte stem cells and paracrine factors for melanocyte regeneration in vitiligo  °­Èñ¿µ(¾ÆÁÖÀÇ´ë) 
±³À°½Ã°£ 04-06 337È£ 14:10~14:30 Pratical tips for the treatment of segmental vitiligo  À̵¿À±(¼º±Õ°üÀÇ´ë) 
±³À°½Ã°£ 04-06 337È£ 14:30~14:50 Protocols of phototherapy in vitiligo treatment  ½ÅÁ¤Çö(ÀÎÇÏÀÇ´ë) 
±³À°½Ã°£ 04-06 337È£ 14:50~15:10 The bottomline of surgical treatments of vitiligo  ¹ÚÁöÈÆ(¿ìÅÂÇÏÇѽ°æÇǺΰú) 
È޽Ġ04-06 337È£ 15:10~15:40 coffee break  () 
±³À°½Ã°£ 04-06 337È£ 15:40~16:10 FoxP3 regulatory T cells in immune-mediated tissue injury  ÃÖÀ±¼®(Ãæ³²ÀÇ´ë Ç÷¾×³»°ú) 
±³À°½Ã°£ 04-06 337È£ 16:10~16:30 Introduction of recent clinical trials and upcoming targeted medical therapy  ¹èÁ¤¹Î(°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 04-06 337È£ 16:30~16:50 Immune checkpoint blockers and vitiligo  ÃÖÁ¾¿ø(Ãæ³²ÀÇ´ë) 
±³À°½Ã°£ 04-06 337È£ 16:50~17:10 Comorbidities of vitiligo and laboratory tests for evaluation of comorbidities  ÀÌÈñÁ¤(Â÷ÀÇ°ú´ë) 
±³À°½Ã°£ 04-06 337È£ 17:10~18:00 Development of vitiligo after immunotherapy for breast cancer  ±èÁ¦¹Î(¿¬¼¼ÀÇ´ë) 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" ¼¼ºê¶õ½ºº´¿ø ´ëÇѹé¹ÝÁõÇÐȸ Á¦ 10Â÷ ½ÉÆ÷Áö¾ö : 2019-04-06""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û ´ëÇÑ»êºÎÀΰúÀÇ»çȸ Á¦41Â÷ Ãá°èÇмú´ëȸ : 2019-04-07
´ÙÀ½±Û ±¤ÁÖÀü³²°³¿ø³»°úÀÇ»çȸ Ãá°èÇмú´ëȸ : 2019-04-06
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
255 ¼­¿ï »ï¼º¼­¿ïº´¿ø ¾ÓÄÚ¸£¼­¿ï 2018 : 2018-09-14 0 555 2018-07-28
254 ¼­¿ï ¼­¿ïƯº°½ÃÀÇ»çȸ °­ÀÇ(Àú½ÅÀåÄ¡·á, ¹æ»ç¼±Ä¡·á) : 2018-09-13 0 1,161 2018-07-28
253 ¼­¿ï °í·Á´ëÇб³±¸·Îº´¿ø 1) Á¡¸·Áúȯ 2) ÇǺΠ¸é¿ªÇÐ : 2018-09-13 0 839 2018-07-28
252 ¼­¿ï »ï¼º¼­¿ïº´¿ø ¾ÓÄÚ¸£¼­¿ï 2018 : 2018-09-13 0 438 2018-07-28
251 ºÎ»ê ´ëÇÑ°£ÇÐȸ ºÎ»ê¿ï»ê°æ³²Áöȸ Áý´ãȸ : 2018-09-13 0 599 2018-07-28
250 °æ±â ÇѸ²´ëÇб³¼º½Éº´¿ø ÀӽŠ¹× ¼öÀ¯±â°£ Áß ¾à¹° Ä¡·á : 2018-09-12 0 666 2018-07-28
249 Ãæ³² ´ëÇÑ°¡Á¤ÀÇÇÐȸ °»³â±â È£¸£¸ó Ä¡·áÀÇ ÃÖ½ÅÁö°ß : 2018-09-12 0 604 2018-07-28
248 ¼­¿ï »ï¼º¼­¿ïº´¿ø ¾ÓÄÚ¸£¼­¿ï 2018 : 2018-09-12 0 686 2018-07-28
247 ÀÎõ ÀÎÇÏ´ëÇб³º´¿ø ³ì³»ÀåȯÀÚÀÇ ¾à¹°Ä¡·á : 2018-09-11 0 406 2018-07-28
246 ÃæºÏ 2018³â ÃæºÏ´ëÇб³º´¿ø ºñ´¢ÀÇÇаú ¿¬¼ö°­Á : 2018-09-11 0 674 2018-07-28
245 ¼­¿ï ´ëÇѾȰúÇÐȸ ¼­¿ï ³²ºÎ Áöȸ ¿¬¼ö ±³À° : 2018-09-10 0 709 2018-07-28
244 ¼­¿ï Á¦ 1ȸ °­ºÏ»ï¼ºº´¿ø ¼Ò¾Æû¼Ò³â°ú °³¿øÀÇ ¿¬¼ö°­Á : 2018-09-09 0 765 2018-07-28
243 ¼­¿ï 2018³â ´ëÇѼҾƼÒÈ­±â¿µ¾çÇÐȸ ¼Ò¾Æû¼Ò³â ¿µ¾ç ½ÉÆ÷Áö¾ö : 2018-09-09 0 765 2018-07-28
242 ¼­¿ï 2018³âµµ ´ëÇÑ°¡Á¤ÀÇÇаúÀÇ»çȸ Ãß°èÇмú´ëȸ ¹× Á¦40ȸ ¿¬¼ö°­Á : 2018-09-09 1 1,341 2018-07-28
241 ´ë±¸ ´ëÇÑ°ñÀýÇÐȸ Á¦1ȸ »óÁö°ñÀý ½ÉÆ÷Áö¾ö : 2018-09-09 0 676 2018-07-28
1391 | 1392 | 1393 | 1394 | 1395 | 1396 | 1397 | 1398 | 1399 | 1400
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷